Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17?018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than IBD

Dai Cong; Jiang Min; Sun Ming‐Jun

首页> 外文期刊>Alimentary pharmacology & therapeutics. >Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17?018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than IBD

【24h】

Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17?018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than IBD

机译：字母：在17岁时，在17例患者中提高克罗恩病或溃疡性结肠炎的风险，同时用抗TNFα剂，特别是依那西普治疗，特别是IBD的自身免疫疾病

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Alimentary pharmacology & therapeutics.》 |2019年第7期|共2页
作者
Dai Cong; Jiang Min; Sun Ming‐Jun;
展开▼
作者单位

Department of Gastroenterology First Affiliated HospitalChina Medical UniversityShenyang City;

Department of Gastroenterology First Affiliated HospitalChina Medical UniversityShenyang City;

Department of Gastroenterology First Affiliated HospitalChina Medical UniversityShenyang City;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17?018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than IBD [J] . Dai Cong, Jiang Min, Sun Ming‐Jun Alimentary pharmacology & therapeutics. . 2019,第7期

机译：字母：在17岁时，在17例患者中提高克罗恩病或溃疡性结肠炎的风险，同时用抗TNFα剂，特别是依那西普治疗，特别是IBD的自身免疫疾病
2. Use of Anti-TNF alpha Agents and Time to First-time Surgery in Paediatric Patients with Ulcerative Colitis and Crohn's Disease [J] . Larsen Michael Due, Qvist Niels, Nielsen Jan, Journal of Crohn’s & colitis . 2016,第6期

机译：小儿溃疡性结肠炎和克罗恩病患者使用抗TNFα药物的时间和首次手术时间
3. Assessment of Inflammatory Burden Identifies Crohn's Disease and Ulcerative Colitis Patient Groups with Different Disease-Driving Pathways and Therapeutic Response to Anti-TNF Treatment [J] . Baribaud Frederic, Pavlidis Stelios, Loza Matthew, The American Journal of Gastroenterology . 2016,第Suppla1期

机译：评估炎症负担可确定克罗恩病和溃疡性结肠炎患者组的疾病驱动途径和抗TNF治疗的治疗反应
4. Analysis of integrated inflammatory bowel disease mouse models to assess their disease driving pathways and relevance for Crohn’s disease and Ulcerative colitis [C] . Weiwei Schultz, Calixte Monast, Mathias Hesse, IEEE International Conference on Bioinformatics and Biomedicine . 2018

机译：分析综合性炎症性肠病小鼠模型以评估其疾病驱动途径以及与克罗恩病和溃疡性结肠炎的相关性
5. The Economic Evaluation of Early Intervention with Anti-TNF-α Treatments in Pediatric Crohn’s Disease [D] . Bashir, Naazish Sultana 2019

机译：小儿克罗恩病早期干预抗TNF-α治疗的经济评价
6. A114 ASSESSMENT OF INFLAMMATORY BURDEN IDENTIFIES CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENT GROUPS WITH DIFFERENT DISEASE-DRIVING PATHWAYS AND THERAPEUTIC RESPONSE TO ANTI-TNF TREATMENT [O] . S Pavlides, M Loza, P Branigan, 2018

机译：A114评估炎症性负载病的克罗恩病和溃疡性结肠炎患者组的疾病驱动途径和对TNF-α治疗的反应性
7. Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than IBD [O] . Cong Dai, Min Jiang, Ming-Jun Sun 2019

机译：字母：在17日018名患者中提高克罗恩病或溃疡性结肠炎的风险，同时在抗TNFα剂，特别是依那西的治疗，特别是IBD的自身免疫疾病

Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17?018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than IBD

著录项

相似文献

相关主题

期刊订阅